A Population-Based analysis of quality indicators in CKD

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 5, 2017, Pages 727-733

  Manns, Liam ^a   Scott Douglas, Nairne ^a,b,c,d   Tonelli, Marcello ^a,b,c,e   Weaver, Robert ^a,b   Tam Tham, Helen ^a,d   Chong, Christy ^a   Hemmelgarn, Brenda ^a  

^a Interdisciplinary Chronic Disease Collaboration   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e ALBERTA HEALTH SERVICES   (Canada)

Author keywords

Adult; Albumins; Albuminuria; Angiotensin Receptor; Angiotensin Receptor Antagonists; Angiotensin Converting Enzyme Inhibitors; Antagonists; Chronic Disease; Creatinine; Diabetes mellitus; Health Care Quality, Access, and Evaluation; Humans; Hydroxymethylglutaryl CoA Reductase Inhibitors; Kidney Function Tests; Quality Improvement; Quality Indicators, Health Care; Renal Insufficiency, Chronic

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER;

ADULT; AGED; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; VERY ELDERLY; ADOLESCENT; ALBERTA; BLOOD; CLINICAL PRACTICE; DIABETIC NEPHROPATHY; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; HEALTH CARE SURVEY; KIDNEY; PATHOPHYSIOLOGY; PRACTICE GAP; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBERTA; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOMARKERS; CREATININE; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PROFESSIONAL PRACTICE GAPS; QUALITY INDICATORS, HEALTH CARE; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85021777507     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08720816     Document Type: Article

References (17)

1. Global Burden of Disease Study 2013 Collaborators: Global, regional,andnational incidence,prevalence, andyears lived with disability for 301 acute and chronic diseases and injuries in 188 countries,1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386: 743-800, 2015
2. Arora P, Vasa P, Brenner D, Iglar K, McFarlane P, Morrison H, Badawi A: Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ 185: E417-E423, 2013
3. Abdel-Kader K, Greer RC, Boulware LE, UnruhML: Primary care physicians’ familiarity, beliefs, and perceived barriers to practice guidelines in non-diabeticCKD: a survey study. BMCNephrol 15: 64, 2014
4. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR; Alberta Kidney Disease Network: Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380: 807-814, 2012
5. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluationandmanagementof chronic kidney disease. Kidney Int Suppl 3 1: 1-150, 2013
6. Giatras I, Lau J, Levey AS; Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group: Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 127: 337-345, 1997
7. Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins onlow density lipoprotein cholesterol, ischaemicheart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423, 2003
8. Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA: A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 23: 1216-1223, 2008
9. Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P, Pannu N, Ahmed SB, MacRae J, Scott-Douglas N, Jindal K, Quinn R, Culleton BF, Wiebe N, Krause R, Thorlacius L, Tonelli M: Overviewof the alberta kidney disease network. BMCNephrol 10: 30, 2009
10. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
11. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43: 1130-1139, 2005
12. Kidney Disease Improving Global Outcomes (KDIGO) Lipid Work Group: KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl 3 3: 259-305, 2013
13. Quan H, Khan N, Hemmelgarn BR, Tu K, Chen G, Campbell N, Hill MD, Ghali WA, McAlister FA; Hypertension Outcome and Surveillance Team of the Canadian Hypertension Education Programs: Validation of a case definition to define hypertension using administrative data. Hypertension 54: 1423-1428, 2009
14. Fukuma S, Shimizu S, Niihata K, Sada KE, Yanagita M, Hatta T, Nangaku M, Katafuchi R, Fujita Y, Koizumi J, Koizumi S, Kimura K, Fukuhara S, Shibagaki Y: Development of quality indicators for care of chronic kidney disease in the primary care setting using electronic health data: A RAND-modified Delphi method [published online ahead of print May 4, 2016]. Clin Exp Nephrol doi: 10.1007/s10157-016-1274-8
15. Shirazian S, Grant CD, Mujeeb S, Sharif S, Kumari P, Bhagat M, Mattana J: Underprescription of renin-angiotensin system blockers in moderate to severe chronic kidney disease. Am J Med Sci 349: 510-515, 2015
16. Schneider MP, Hübner S, Titze SI, Schmid M, Nadal J, Schlieper G, Busch M, Baid-Agrawal S, Krane V, Wanner C, Kronenberg F, Eckardt KU: Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. Kidney Int 88: 1411-1418, 2015
17. Assogba GF, Couchoud C, Roudier C, Pornet C, Fosse S, Romon I, Druet C, Stengel B, Fagot-Campagna A: Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: the ENTRED surveys (2001 and 2007). Diabetes Metab 38: 558-566, 2012